Last reviewed · How we verify
Hypertension
Approved treatments
- Caduet · Pfizer Inc.
Calcium channel antagonist inhibiting transmembrane calcium influx into vascular and cardiac muscle. - Minnebro · Daiichi Sankyo
- Prazosin Hcl · Pfizer
- olmesartan medoxomil-hydrochlorothiazide · Cosette
Olmesartan works by blocking the action of a hormone that causes blood vessels to constrict, allowing blood vessels to relax and blood pressure to decrease. - Candesartan Cilexetil · Alembic
Candesartan cilexetil works by blocking the action of angiotensin II, a hormone that constricts blood vessels, to lower blood pressure and improve heart function. - Lisinopril/HCTZ · Direct_Rx
- Tryvio · Idorsia
Tryvio works by blocking the action of endothelin, a protein that constricts blood vessels and increases blood pressure. - TORSEMIDE
Torsemide inhibits the Na+/K+/2Cl- carrier system in the thick ascending limb of the loop of Henle, leading to increased excretion of sodium, chloride, and water. - CHLORTHALIDONE
Clinical guidelines
- FDA label — 1L|2L|3L+|any
Amlodipine besylate tablets are indicated for the treatment of chronic stable angina. - FDA label — 1L|2L|3L+|any
Amlodipine besylate tablets are indicated for the treatment of vasospastic angina (Prinzmetal's or variant angina). - FDA label — 1L|2L|3L+|any
Amlodipine besylate tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. - FDA label — 1L|2L|3L+|any
Amlodipine besylate tablets are indicated for the treatment of chronic stable angina, vasospastic angina (Prinzmetal's or variant angina), and angiographically documented coronary artery disease in patients without heart failure or an ejection fraction < 40%. - FDA label — 1L|2L|3L+|any
Amlodipine besylate tablets are indicated for the treatment of angiographically documented coronary artery disease in patients without heart failure or an ejection fraction < 40%. - FDA label — 1L|2L|3L+|any
Amlodipine besylate tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. - FDA label — 1L|2L|3L+|any
Amlodipine besylate tablets are indicated for the treatment of chronic stable angina. - FDA label — 1L|2L|3L+|any
Amlodipine besylate tablets are indicated for the treatment of vasospastic angina (Prinzmetal's or variant angina). - FDA label — 1L|2L|3L+|any
Amlodipine besylate tablets are indicated for the treatment of angiographically documented coronary artery disease in patients without heart failure or an ejection fraction < 40%.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape: